Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Peikert, A; Vaduganathan, M; Mc, Causland, F; Claggett, BL; Chatur, S; Packer, M; Pfeffer, MA; Zannad, F; Lefkowitz, MP; Pieske, B; Düngen, HD; McMurray, JJV; Solomon, SD.
Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON-HF.
Eur J Heart Fail. 2022; 24(5): 794-803. Doi: 10.1002/ejhf.2450 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Leading authors Med Uni Graz: Peikert Alexander
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: AIMS: Diabetes is associated with a faster rate of renal function decline in patients with heart failure (HF). Sacubitril/valsartan attenuates the deterioration of renal function to a greater extent in patients with diabetes and HF with reduced ejection fraction compared with renin-angiotensin system inhibitors alone. We assessed whether the same may be true in HF with preserved ejection fraction (HFpEF). METHODS AND RESULTS: In the PARAGON-HF trial in patients with HF and left ventricular ejection fraction of ≥45% (n = 4796), we characterized the effects of sacubitril/valsartan on changes in estimated glomerular filtration rate (eGFR) over a period of 192 weeks, and on the pre-specified renal composite outcome (eGFR reduction of ≥50%, end-stage renal disease, or death attributable to renal causes) in patients with (n = 2388) and without diabetes (n = 2408). The decline in eGFR was greater in patients with diabetes than in those without (-2.6 vs. -1.7 ml/min/1.73 m² per year, p < 0.001), regardless of treatment assignment. Sacubitril/valsartan attenuated decline in eGFR similarly in patients with (-2.2 vs. -2.9 ml/min/1.73 m² per year, p = 0.001) and without diabetes (-1.5 vs. -2.0 ml/min/1.73 m² per year, p = 0.006) (p_interaction for difference in eGFR slopes = 0.40). Compared with valsartan, sacubitril/valsartan reduced the renal composite outcome similarly in patients without diabetes (hazard ratio [HR] 0.42, 95% confidence interval [CI] 0.19-0.91) and those with diabetes (HR 0.54, 95% CI 0.33-0.89; p_interaction = 0.59), as well as across a range of baseline glycated haemoglobin (p_interaction = 0.71). CONCLUSION: Sacubitril/valsartan, compared with valsartan, attenuates the decline of eGFR and reduces clinically relevant kidney events similarly among patients with HFpEF with and without diabetes.
Find related publications in this database (using NLM MeSH Indexing): Aminobutyrates - pharmacology, therapeutic use; Angiotensin Receptor Antagonists - administration & dosage; Biphenyl Compounds - pharmacology, therapeutic use; Diabetes Mellitus - drug therapy, epidemiology; Drug Combinations - administration & dosage; Heart Failure - drug therapy; Humans - administration & dosage; Kidney - drug effects, physiology; Stroke Volume - administration & dosage; Tetrazoles - pharmacology, therapeutic use; Valsartan - pharmacology, therapeutic use; Ventricular Function, Left - administration & dosage
Find related publications in this database (Keywords): Heart failure with preserved ejection fraction; Sacubitril; valsartan; Diabetes; Renal function